URMC Plays Key Role in New Huntington ’s Drug

University of Rochester Medical Center researchers were instrumental in the U.S. Food and Drug Administration ’s recent approval of SD-809 (deutetrabenazine) to treat Huntington’s disease. Deutetrabenazine is the only the second drug authorized by the agency to treat this rare, inherited neurodegenerative disorder.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news